The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
Included in the deal is Diagnomics' minority stake in the Eone-Diagnomics Genome Center, a Korean provider of clinical and consumer genetics products and services.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.
The project has sequenced more than 1,700 individuals from across Asia to high coverage in order to bolster the representation of Asians in genomic research.
